The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

In our group, about 90% of patients with early gastric carcinoma have heartburn, abdominal pain and discomfort in the upper abdomen. The other reason is that some of the lesions are so subtle that ...

BeiGene (BGNE) said Friday the US Food and Drug Administration approved Tevimbra, its drug to treat a form of stomach cancer, in combination with chemotherapy. Tevimbra, or tislelizumab-jsgr, is ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...